MEK/BRAF Combo Rests On Survival Benefit
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The best positioning of GSK’s Tafinlar/Mekinist combo is still in flux as data continues to emerge in the rapidly evolving melanoma space.